Massachusetts Eye and Ear Infirmary
The goal of this clinical trial is to learn if insulin eye drops, added to standard care, can treat persistent corneal epithelial defects (PEDs) in adults age 18 and older. A PED is a corneal surface wound, at least 2 mm across, that has not healed after more than 14 days of standard treatment such as lubricants, antibiotic drops, or a bandage contact lens. The main question it aims to answer is: \- Does adding insulin eye drops (1 IU/mL, four times daily) to standard care increase the proportion of eyes with complete corneal epithelial healing at 8 weeks? The standard care plus insulin eye drops will be compared to standard care plus placebo eye drops (preservative-free saline) to see if insulin leads to more complete healing, faster healing, fewer recurrences, and better symptom relief. They will also assess the safety of the drops and their effects on corneal nerves. Participants will: * Be randomly assigned (1:1) to insulin or placebo drops. Neither participants nor the investigators assessing healing will know which drops are used. The study is single-center (Massachusetts Eye and Ear) and plans to enroll 40 participants, one eye each. * Use the study drops four times daily for up to 8 weeks, along with standard care chosen by their cornea specialist, and return weekly for a fresh, refrigerated supply. * Attend study visits at baseline and at weeks 1, 4, 8, and 12 for visual acuity testing, slit-lamp examination, fluorescein staining and photography of the defect, and imaging of corneal nerves (in vivo confocal microscopy). * Complete symptom questionnaires (pain, foreign body sensation, light sensitivity) at baseline and week 8, and have corneal sensation tested before and after treatment. * Have blood glucose monitored if they have diabetes.
Corneal diseases are a leading cause of blindness worldwide according to the World Health Organization; many are in need of a corneal transplant but with a dearth of available tissue and proper medical/surgical expertise and care, the vast majority remain blind. A common cause of corneal blindness is untreated corneal epithelial defects. And as we explain below, the treatment options are very limited. A persistent corneal epithelial defect (PED) is defined as a failure of the cornea to re-epithelialize within 2 weeks with standard treatment, and is caused by many underlying reasons, including…
Inclusion Criteria: * Adults age 18 and older. * 2\. Focal corneal epithelial defect (≥ 2mm in longest dimension) present for \> 14 days despite standard treatment (e.g. lubrication, antibiotic, bandage contact lens, etc.) Exclusion Criteria: * Active uncontrolled infection in the study eye. * Impending corneal perforation (that requires urgent surgery). * Other ocular comorbidities that would confound healing.
The patients will receive topical regular human insulin diluted to 1 IU/mL in sterile preservative-free normal saline, applied as an eye drop four times a day (QID). Additionally, all interventional arm patients will continue to receive standard-of-care (SoC) therapy for PED as determined by the treating cornea specialist. SoC typically may include a preservative-free lubricant regimen, a fluoroquinolone antibiotic drop QID for prophylaxis, and use of a bandage contact lens or eyelid taping if appropriate.
All patients will continue to receive standard-of-care (SoC) therapy for PED as determined by the treating cornea specialist. SoC typically may include a preservative-free lubricant regimen, a fluoroquinolone antibiotic drop QID for prophylaxis, and use of a bandage contact lens or eyelid taping if appropriate.